SNDX
NASDAQ
US
Syndax Pharmaceuticals, Inc. - Common Stock
$25.15
▲ +$1.27
(+5.32%)
Vol 2.1M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.8B
ROE
-160.5%
Margin
-279.2%
D/E
297.94
Beta
0.47
52W
$9–$23
Wall Street Consensus
20 analysts · Apr 20268
Strong Buy
11
Buy
1
Hold
0
Sell
0
Strong Sell
95.0%
Buy Rating
Price Chart
Similar Stocks
SRPT
Sarepta Therapeutics Inc
$2.3B
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
GRAL
Grail Inc
$3.3B
RLAY
Relay Therapeutics Inc
$1.5B
MLYS
Mineralys Therapeutics Inc
$2.9B
DAWN
Day One Biopharmaceuticals Inc
$956.9M
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.60 | $-0.78 | $-0.18 |
| Sep 2025 | $-0.73 | $-0.70 | +$0.03 |
| Jun 2025 | $-1.04 | $-0.83 | +$0.21 |
| Mar 2025 | $-1.36 | $-0.98 | +$0.38 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -130.4% | -130.5% | -130.5% | -130.5% | -160.5% | -160.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -189.3% | -428.5% | -428.5% | -428.5% | -279.2% | -279.2% |
| Gross Margin | 96.6% | — | — | — | 95.4% | 95.4% |
| D/E Ratio | 219.27 | 219.27 | 219.27 | 219.27 | 297.94 | 297.94 |
| Current Ratio | 4.71 | 4.71 | 4.71 | 4.71 | 4.64 | 4.64 |
Key Ratios
ROA (TTM)
-49.6%
P/S (TTM)
16.37
P/B
3.9
EPS (TTM)
$-3.60
CF/Share
$-2.59
Rev Growth 3Y
-44.7%
52W High
$22.73
52W Low
$8.58
$8.58
52-Week Range
$22.73
How does SNDX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SNDX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
16.4
▲
27%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
3.9
▲
59%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SNDX profitability vs Biotechnology peers
ROE
-160.5%
▼
139%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-279.2%
▲
3%
above
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
95.4%
▲
21%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-49.6%
▼
6%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
SNDX financial health vs Biotechnology peers
D/E ratio
297.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.6
▲
5%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.5
▼
51%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
SNDX fundamentals radar
SNDX
Peer median
Industry
SNDX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio